Mutagenesis methods and compositions
AssigneeBerlex Laboratories, Inc.
InventorsWilliam H. Andrews, Michael J. Morser, Laura R. Vilander
Life of this patent
Estimating the term…
Abstract
Methods and reagents for oligonucleotide-directed mutagenesis of a target nucleic acid are provided. In these methods a mutagenic oligonucleotide introduces a desired mutation at one site and, at a second site, introduces or eliminates a restriction site, allowing one to screen for the desired mutation by restriction analysis. Also provided are vectors and kits for performing such mutagenesis methods.
Claims12
A method for introducing a plurality of mutations to a nucleic acid construct comprising a target sequence, a first marker sequence encoding a first protein having an inoperable first marker activity, and a second marker sequence encoding a second protein having an operable second marker activity, said method comprising the steps of:
- (a) annealing to a single-stranded form of said nucleic acid construct
- a first oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said first oligonucleotide is selected so as to change a nucleotide at a first position of said nucleic acid construct where said first position is within said target sequence, and to introduce or remove a first restriction site at a second position of said nucleic acid construct;
- a second oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said second oligonucleotide is selected so as to change one or more nucleotides in said first marker sequence to produce a mutated first marker sequence in a manner which results in an operable first marker activity;
- and
- a third oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said third oligonucleotide is selected so as to change one or more nucleotides in said second marker sequence to produce a mutated second marker sequence in a manner which results in an inoperable second marker activity, thereby forming a primary annealed product;
- (b) transforming a host cell with said primary annealed product;
- (c) screening or selecting progeny of transformed host cells having said operable first marker activity;
- (d) identifying progeny screened or selected and containing a mutated nucleic acid construct containing a mutated target sequence and having said introduced or removed first restriction site;
- (e) annealing to a single-stranded form of said mutated nucleic acid construct
- a fourth oligonucleotide having a sequence substantially complementary to a portion of said mutated nucleic acid construct, wherein the sequence of said fourth oligonucleotide is selected so as to change a nucleotide at a first position of said mutated nucleic acid construct where said first position is within said mutated target sequence, and to introduce or remove a second restriction site at a second position of said mutated nucleic acid construct;
- a fifth oligonucleotide having a sequence substantially complementary to a portion of said mutated nucleic acid construct, wherein the sequence of said fifth oligonucleotide is selected so as to restore said first marker sequence in a manner which results in said inoperable first marker activity;
- and
- a sixth oligonucleotide having a sequence substantially complementary to a portion of said mutated nucleic acid construct, wherein the sequence of said sixth oligonucleotide is selected so as to restore said second marker sequence in a manner which results in said operable second marker activity, thereby forming a secondary annealed product;
- (f) transforming a host cell with said secondary annealed product;
- (g) screening or selecting progeny of transformed host cells having said operable second marker activity;
- and
- (h) identifying progeny screened or selected and containing a further mutated nucleic acid construct having said introduced or removed second restriction site.
A kit for introducing one or more mutations to a nucleic acid construct comprising:
- (a) said nucleic acid construct comprising a ColE1 origin of replication, a polylinker within a lacZ gene for inserting a target sequence, a first marker sequence encoding a first protein having an inoperable first marker activity, and a second marker sequence encoding a second protein having an operable second marker activity;
- (b) a first oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said first oligonucleotide is selected so as to change one or more nucleotides in said first marker sequence to produce a mutated first marker sequence in a manner which results in an operable first marker activity;
- (c) a second oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said second oligonucleotide is selected so as to change one or more nucleotides in said second marker sequence to produce a mutated second marker sequence which results in an inoperable second marker activity;
- (d) a third oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said third oligonucleotide is selected so as to restore said first marker sequence in a manner which results in said inoperable first marker activity;
- (e) a fourth oligonucleotide having a sequence substantially complementary to a portion of said nucleic acid construct, wherein the sequence of said fourth oligonucleotide is selected so as to restore said second marker sequence in a manner which results in said operable second marker activity;
- (f) a DNA polymerase;
- (g) deoxyribonucleotides;
- (h) a DNA ligase:
- and
- (i) buffers suitable for activity of said DNA polymerase and said DNA ligase.
Dependencies are inferred from the claim text.